Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
Key Highlights
- ➤Six abstracts accepted for poster presentation at ASH 2026
- ➤New analyses examine RYTELO dosing, hematologic responses and cytopenias in lower-risk MDS
- ➤RYTELO plus ruxolitinib updated results from the IMproveMF trial will be presented
- ➤Phase 1/1b imetelstat combination trial in relapsed acute myeloid leukemia will be presented
Expert Statements
Joseph E. Eid, Executive Vice President, Research and Development and Chief Medical Officer of Geron
“As we continue to build on the evidence supporting RYTELO in lower-risk MDS, understanding the relationship between dosing, hematologic response and cytopenias is important to informing its appropriate use in clinical practice.”
Joseph E. Eid, Executive Vice President, Research and Development and Chief Medical Officer of Geron
“The data to be presented at ASH further supports the scientific rationale for our approved dosing regimen, while the broader research continues to deepen our understanding of imetelstat’s clinical and biological activity across hematologic malignancies.”
Joseph E. Eid, Executive Vice President, Research and Development and Chief Medical Officer of Geron
“Together, these efforts reflect our commitment to deepening our understanding of the science of telomerase inhibition.”
FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68(th) American Society of Hematology (ASH) Annual Meeting, to be held December 12-16, 2026, in New Orleans, LA. The presentations include new analyses providing further insight into the clinical activity and approved dosing regimen of RYTLEO® (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).
“As we continue to build on the evidence supporting RYTELO in lower-risk MDS, understanding the relationship between dosing, hematologic response and cytopenias is important to informing its appropriate use in clinical practice,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “The data to be presented at ASH further supports the scientific rationale for our approved dosing regimen, while the broader research continues to deepen our understanding of imetelstat’s clinical and biological activity across hematologic malignancies. Together, these efforts reflect our commitment to deepening our understanding of the science of telomerase inhibition.”
Get started
Create a free account to read the full story.